Sep 30, 2026 08:01AM
Sep 30, 2026 08:00AM
Aug 11, 2026 08:00AM
Aug 6, 2026 08:00AM
Aug 6, 2026 08:00AM
Jul 7, 2026 08:01AM
Jul 7, 2026 08:00AM Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients
May 5, 2026 04:30PM
Apr 17, 2026 04:05PM
Apr 17, 2026 04:05PM
Mar 24, 2026 09:50AM
Mar 23, 2026 08:01AM
Mar 23, 2026 08:00AM
Mar 23, 2026 08:00AM Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Mar 12, 2026 08:00AM
Feb 3, 2026 08:01AM
Feb 3, 2026 08:00AM
Dec 29, 2025 08:00AM
Dec 29, 2025 08:00AM
Nov 12, 2025 08:00AM
May 27, 2025 08:01AM Theriva Biologics (TOVX) Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Trial
May 27, 2025 08:00AM
May 7, 2025 07:00AM
May 7, 2025 07:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM
Mar 6, 2025 04:10PM
Dec 5, 2024 08:00AM Theriva Biologics (TOVX) Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01
Dec 5, 2024 08:00AM
Nov 12, 2024 08:00AM
Oct 16, 2024 08:02AM
Oct 16, 2024 08:00AM
Sep 23, 2024 08:00AM
Aug 13, 2024 08:00AM
Jul 31, 2024 08:16AM Theriva Biologics (TOVX) Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
Jul 31, 2024 08:15AM
May 23, 2024 08:15AM
May 23, 2024 08:15AM
Nov 13, 2023 08:00AM
Aug 8, 2023 08:00AM
Jun 27, 2023 04:14PM
Jun 27, 2023 04:10PM Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer
May 11, 2023 08:00AM
Mar 30, 2023 08:00AM
Jan 17, 2023 08:00AM
Nov 10, 2022 04:45PM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All